Please assess the completion status of the following clinical trial:

Trial Title: Vascular Dysfunction in Hypertensive Postmenopausal Women

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Women.~* \> 1year post menopausal.~* Age range 50-70 years~* Resting ECG in normal limits~* Standard blood chemistry within normal limits~* Systolic blood pressure: \<130mm Hg for normotensives; \>130mm Hg for hypertensives.~* Diastolic blood pressure: \< 80mm Hg for normotensives; \> 80mm Hg for hypertensives.~Exclusion Criteria:~* History of cardiovascular disease~* Blood clots or stroke~* Cancer~* Diabetes~* Kidney or Liver disease~* Obesity (BMI\>35kg/m2)~* Pregnant/Breast feeding~* Current use of hormone therapy~* Current use of tobacco products~* High cholesterol~* Current use of anti-hypertensive meds

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Normotensive (Type: OTHER): Normotensive PMW will complete an experimental visit to assess vascular function. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visit to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
- Hypertensives (Type: EXPERIMENTAL): Hypertensive women will be tested at baseline and then administered Losartan 50 mg once a day at night for 14 days. Vascular function is measured at baseline and again after 2 weeks of losartan. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visits to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.

Based on this trial design, predict the completion outcome and termination type (if applicable).